Ball, Emily, Purchase, Thomas ![]() |
Official URL: http://dx.doi.org/10.1136/archdischild-2022-324432
Abstract
Background It is estimated that 1 in 300 people will experience anaphylaxis at some point1 with approximately 20–30 deaths per year in the UK from anaphylaxis.2 The treatment, investigation and follow-up of patients with anaphylaxis are frequently suboptimal, with approximately 50% of anaphylaxis episodes not treated appropriately with intramuscular epinephrine (adrenaline),3 despite previous guidance recommending epinephrine as first-line treatment. This is often due to a failure to recognise anaphylaxis which can be difficult due to the variety of signs and symptoms that may occur, none of which are specific to anaphylaxis (defined in box 1).
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | BMJ Publishing Group |
ISSN: | 1743-0585 |
Date of First Compliant Deposit: | 17 May 2023 |
Date of Acceptance: | 30 November 2022 |
Last Modified: | 27 Sep 2023 14:42 |
URI: | https://orca.cardiff.ac.uk/id/eprint/159568 |
Actions (repository staff only)
![]() |
Edit Item |